Arcturus Therapeutics Holdings Inc. (ARCT) is gearing up to report results from its phase 1b study using its inhaled messenger RNA [mRNA] treatment known as ARCT-032 for the treatment of patients with ...

Without a doubt, the brightest star in the summer night sky is Arcturus. It’s the second-brightest star in our night skies throughout the year. Only Sirius, the brightest star in the constellation ...

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

Arcturus has developed the first sa-mRNA COVID-19 vaccine, Kostaive, in the world. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative mRNA ...

On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while maintaining a Neutral rating, reflecting a selective stance toward SMID-cap biotech ...